Medscape (3/8, Lyss, Subscription Publication) reports, “A large, retrospective study shows how germline genetic testing has evolved over time in women with breast or ovarian cancer and reveals a path forward for testing these patients.” The study’s authors “found racial and ethnic disparities in genetic testing as well as ‘persistent underuse’ of testing in patients with ovarian cancer.” The findings were published in the Journal of Clinical Oncology.
